JOSEPH PAUL DUDA
Pharmacy in Morgantown, WV
License number
Pennsylvania RP441543
Category
Pharmacy
Type
Pharmacist
Address
Address
2
Morgantown, WV 26508
Pennsylvania
Pennsylvania
Personal information
See more information about JOSEPH PAUL DUDA at radaris.comName
Address
Phone
517 S Waterloo Rd, Devon, PA 19333
7015 Redcoat Dr, Flourtown, PA 19031
634 Cedar St, Freeland, PA 18224
554 Club Cir, Daniels, WV 25832
418 Roberts Run Rd, Mount Morris, PA 15349
Professional information
Phenytoin Sodium Pharmaceutical Compositions
US Patent:
6620432, Sep 16, 2003
Filed:
May 11, 2001
Appl. No.:
09/852761
Inventors:
William J. Addicks - Morgantown WV
Joseph P. Duda - Morgantown WV
Daniel A. Snider - Morgantown WV
Kerry R. Benson - Morgantown WV
Joseph P. Duda - Morgantown WV
Daniel A. Snider - Morgantown WV
Kerry R. Benson - Morgantown WV
Assignee:
Mylan Pharmaceuticals Inc. - Morgantown WV
International Classification:
A61K 920
US Classification:
424451, 424464, 424484, 424485, 424486, 424487, 424488, 424469, 514770, 5147723, 514773, 514774, 514777, 514778, 514779, 514781, 514782, 514783
Abstract:
A pharmaceutical composition is provided containing an admixture of phenytoin sodium and an erodible matrix which extends the release of the phenytoin sodium over about a two hour period. The erodible matrix comprises binder(s) and diluent(s) which control the release of drug from the pharmaceutical composition. The erodible matrix can further comprise an alkaline pH modifier.
Phenytoin Sodium Pharmaceutical Compositions
US Patent:
6274168, Aug 14, 2001
Filed:
Feb 23, 1999
Appl. No.:
9/255705
Inventors:
William J Addicks - Morgantown WV
Joseph P Duda - Morgantown WV
Daniel A. Snider - Morgantown WV
Kerry R Benson - Morgantown WV
Joseph P Duda - Morgantown WV
Daniel A. Snider - Morgantown WV
Kerry R Benson - Morgantown WV
Assignee:
Mylan Pharmaceuticals Inc. - Morgantown WV
International Classification:
A61K 920, A61K 948, A61K 916
US Classification:
424451
Abstract:
A pharmaceutical composition is provided containing an admixture of phenytoin sodium and an erodible matrix which extends the release of the phenytoin sodium over about a two hour period. The erodible matrix comprises binder(s) and diluent(s) which control the release of drug from the pharmaceutical composition. The erodible matrix can further comprise an alkaline pH modifier.